Microbio Co., Ltd. Announces Promising Results of “MS-20” as an Add-on Therapy for Ulcerative Colitis
sdecoret
Press Releases
Microbio Co Ltd  
March 17, 2025

Microbio Co., Ltd. Announces Promising Results of “MS-20” as an Add-on Therapy for Ulcerative Colitis

TAIPEI, March 17, 2025 /PRNewswire/ -- Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in combination with current medications for ulcerative colitis

avatar profile Olean Times Herald

Olean Times Herald


Local & Social